Design Therapeautics, Inc. share price logo

Design Therapeautics, Inc. Share Price

NASDAQ: DSGN

Small Cap

$10.53

-0.18

(-1.68%)

as on

Design Therapeautics, Inc. Stock Performance

as on March 28, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $10.33
    $10.80
    downward going graph

    1.90%

    Downside

    2.56%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.60
    $11.23
    downward going graph

    75.31%

    Downside

    6.65%

    Upside

    downward going graph

Design Therapeautics, Inc. share price movements today

Previous Close
$10.71
Open
$10.68
Volume
365.9K
Day's Low - High
$10.33 - $10.80
52 Week Low - High
$2.60 - $11.23

Design Therapeautics, Inc. Historical Returns

1 Month Return
+ 0.86 %
3 Month Return
+ 9.35 %
1 Year Return
+ 150.12 %
3 Year Return
+ 91.45 %
5 Year Return
-74.62 %

Design Therapeautics, Inc. Stock Fundamentals & Key Indicators

Check Design Therapeautics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$660.5M

EPS (TTM)

-1.404

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-78.4M

Revenue (TTM)

33.0K

Profit Margin

0.00%

Return On Equity TTM

-30.71%

Design Therapeautics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Design Therapeautics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Design Therapeautics, Inc. image
Design Therapeautics, Inc.
HOLD$660.5M-74.62%NA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$43.5B132.92%140.848.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.2B101.77%29.5832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.8BNA112.585.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.0B54.69%18.2531.41%

Stock Returns calculator for Design Therapeautics, Inc. Stock including INR - Dollar returns

The Design Therapeautics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Design Therapeautics, Inc. investment value today

Current value as on today

₹2,60,628

Returns

₹1,60,628

(+160.63%)

Returns from Design Therapeautics, Inc. Stock

₹1,50,119 (+150.12%)

Dollar Returns*

₹10,509 (+10.51%)

Analyst Recommendation on Design Therapeautics, Inc. Stock

Based on 8 analysts

HOLD

0.00%

Buy

62.50%

Hold

37.50%

Sell

Based on 8 analysts, 62.5% of analysts recommend a 'HOLD' rating for Design Therapeautics, Inc.. Average target price of $14.67

Design Therapeautics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Design Therapeautics, Inc..

What analysts predicted

28.22%UPSIDE

Target Price

$14.67

Current Price

$10.53

Analyzed by

8 Analysts

Target

$14.67

Design Therapeautics, Inc. target price $14.67, a slight upside of 28.22% compared to current price of $10.53. According to 8 analysts rating.

Design Therapeautics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Design Therapeautics, Inc. Stock has increased by 27% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:27% versus previous 30 day period

Design Therapeautics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
-
0
-
-
-
0
-
-
-
Gross Profit
0
0
0
0
0
0
0
0
-14
Operating Income
-18
-15
-14
-15
-16
-16
-20
-21
-19
EBITDA
-18
-14
-14
-14
-16
-16
-20
-18
-16
Interest Expense
-
0
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-15
-11
-11
-11
-13
-13
-17
-19
-16
Income Tax Expense
0
2
0
-
-
-
-
-
-
Net Income
-15
-11
-11
-11
-13
-13
-17
-19
-16
Net Profit Margin
0.00%
-1413.13%
0.00%
0.00%
0.00%
-2321.60%
0.00%
0.00%
0.00%

Design Therapeautics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
0
0
-
-
-
-
Gross Profit
0
0
0
0
0
0
Operating Income
-1
-8
-35
-67
-78
-62
EBITDA
-1
-8
-35
-67
-66
-48
Interest Expense
-
-
0
4
-
-
Depreciation
-
0
0
0
0
0
Income Before Tax
-2
-8
-35
-63
-66
-49
Income Tax Expense
0
0
0
-4
0
-
Net Income
-2
-8
-35
-58
-66
-49
Net Profit Margin
-245.44%
-3663716.81%
0.00%
0.00%
0.00%
0.00%

Design Therapeautics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-11
-11
-11
-13
-13
-17
-19
-16
-15
Operating Cash Flow
-12
-12
-11
-9
-9
-16
-14
-11
-11
Investing Cash Flow
5
20
27
-5
1
7
20
6
-11
Financing Cash Flow
0
0
0
0
0
0
0
0
25
Change in Cash
-6
8
16
-15
-7
-8
6
-4
1

Design Therapeautics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-8
-35
-63
-66
-49
-69
Operating Cash Flow
-8
-29
-51
-58
-43
-54
Investing Cash Flow
-33
-53
-220
52
43
22
Financing Cash Flow
44
379
0
0
0
25
Change in Cash
2
296
-272
-5
1
-5

Global Institutional Holdings in Design Therapeautics, Inc.

Funds
Holdings
Almitas Capital LLC
5.37%
Dimensional Fund Advisors, Inc.
0.49%
Baker Bros Advisors LP
3.7%
Vanguard Group Inc
2.7%
RA Capital Management, LLC
2.42%
See all

Insights on Design Therapeautics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, DSGN stock has moved up by 60.3%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, DSGN has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, DSGN has outperformed top 5 stocks with highest market-cap in its industry

About Design Therapeautics, Inc.

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
OrganisationDesign Therapeautics, Inc.
Headquarters6005 Hidden Valley Road, Carlsbad, CA, United States, 92011
IndustryHealthcare
CEOMr. Pratik Shah Ph.D.
E-voting on sharesClick here to vote

Key Management of Design Therapeautics, Inc.

Name

Title

Mr. Pratik Shah Ph.D.

Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson

Dr. Sean Jeffries Ph.D.

Chief Operating Officer

Mr. Mustapha Parekh

General Counsel

Dr. Chris M. Storgard M.D.

Chief Medical Officer

Dr. Aseem Z. Ansari Ph.D.

Co-Founder & Scientific Advisor

Ms. Julie D. Burgess CPA

Chief Accounting Officer

Mr. Doane Chilcoat Ph.D.

Chief Technology Officer

Dr. Tadimeti S. Rao Ph.D.

Chief Scientific Officer

Mr. Jim Kerr

Chief of Manufacturing & Product Development

Dr. Chengzhi Zhang Ph.D.

Chief Chemist

FAQs

What is Design Therapeautics, Inc. share price today?

Design Therapeautics, Inc. share price today is $10.53 as on at the close of the market. Design Therapeautics, Inc. share today touched a day high of $10.8 and a low of $10.33.

What is the 52 week high and 52 week low for Design Therapeautics, Inc. share?

Design Therapeautics, Inc. share touched a 52 week high of $11.23 on and a 52 week low of $2.6 on . Design Therapeautics, Inc. stock price today i.e. is closed at $10.53,which is 6.23% down from its 52 week high and 305.00% up from its 52 week low.

What is Design Therapeautics, Inc.'s market capitalisation today?

Design Therapeautics, Inc. market capitalisation is $0.00T as on .

How to invest in Design Therapeautics, Inc. Stock (DSGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Design Therapeautics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Design Therapeautics, Inc. Shares that will get you 0.1425 shares as per Design Therapeautics, Inc. share price of $10.53 per share as on March 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy Design Therapeautics, Inc. Stock (DSGN) from India?

Indian investors can start investing in Design Therapeautics, Inc. (DSGN) shares with as little as ₹94.651 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.51 in Design Therapeautics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Design Therapeautics, Inc. share’s latest price of $10.53 as on March 28, 2026 at 1:29 am IST, you will get 0.9497 shares of Design Therapeautics, Inc.. Learn more about fractional shares .

What are the returns that Design Therapeautics, Inc. has given to Indian investors in the last 5 years?

Design Therapeautics, Inc. stock has given -74.62% share price returns and 29.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?